ALIFE2 Study Call for participation

Slides:



Advertisements
Similar presentations
Venous Thrombo-embolism In Pregnancy
Advertisements

Venous Thromboembolism: Risk Assessment and Prophylaxis
Indications for a thrombophilia workup in Obstetrics Helen H. Kay, MD February, 2005.
1 Classification n APS, n Hereditary Thrombophilias, n Unexplained RPL,
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Increasingly, women who are asymptomatic present in pregnancy with a known thrombophilia, typically detected because of screening following identification.
Regional Anesthetics and Anticoagulation Marie Sankaran Raval M.D. Boston Medical Center Department of Anesthesiology Nina Zachariah M.D.
Vascular Pharmacology
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
Thrombophilia Rose Marie Meier Reproductive medicine Genk - Belgium.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Anticoagulant therapy in RPL Dr. Z. Heidar Assistant professor SBMU.
Chapter Ten Venous Disease Coalition Hypercoagulability VTE Toolkit.
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
Bob Silver, MD University of Utah Health Sciences Thrombophilias in Obstetrics Modified from a presentation to the Society of Maternal Fetal Medicine by.
Judicious Use of Anticoagulation: A Case-Based Approach
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Max Brinsmead MB BS PhD May A summary of...  RCOG Green-top Guideline number 17 April 2011  “The Investigation and Treatment of Couples with Recurrent.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Thrombophilia National Haemophilia Director
Hypercoagulable States. Acquired versus inherited Acquired versus inherited “Provoked” vs idiopathic VTE “Provoked” vs idiopathic VTE Who should be tested.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
Charles J. Lockwood, M.D. The Anita O’Keefe Young Professor and Chair Department of Obstetrics, Gynecology and Reproductive Sciences Yale University School.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Dose-Escalated Low Molecular Weight Heparin Provides Effective Anticoagulation for Women with Mechanical Heart Valves During Pregnancy: A Single-Centre.
Venous thromboembolic disease
Thrombophilia Made Simple for Obstetricians
Management issues in other thrombophilia Ng Heng Joo Department of Haematology Singapore General Hospital.
Postpartum period in women with systemic lupus erythematosus BY DR KH ELMIZADEH.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Shannon M. Bates, MDCM, MSc Ian A. Greer, MD, FMedSci, FCCP Saskia Middeldorp, MD, PhD David.
UOG Journal Club: May 2016 Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis S. Roberge, S. Demers, K.H.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Women’s Issues and Blood Clotting
The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.
Dep. Of Hemato-Oncology R1. Choi In-Ah D-dimer Testing to Determine the Duration of Anticoagulation Therapy Gualtiero Palareti,M.D., Benilde Cosmi, M.D.,
Deficiencies of Proteins C, S and Antithrombin and Activated Protein C Resistance – Their Involvement in the Occurrence of Arterial Thromboses Report PGY.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Efficacy of Renally Adjusted Treatment Dose Enoxaparin in Obese Patients with Severe Renal Impairment Alexas Polk, PharmD PGY-1 Pharmacy Resident St. Joseph’s/Candler.
UOG Journal Club: May 2016 Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis S. Roberge, S. Demers, K.H.
Venous Thromboembolism Prophylaxis for Medical Inpatients
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Pregnancy in women with antiphospholipid syndrome
Immunological disorder during pregnancy
Recurrent Miscarriage
Antiphospholipid Antibody Syndrome
Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history : a randomized trial Katie M. Groom, MBBS, PhD,
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Clinical Knowledge Summaries CKS Pulmonary embolism (PE)
James M. Roberts, M.D., Leslie Myatt, Ph.D.,et al.
Recurrent Pregnancy Loss
Autoimmune disease in pregnancy
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Discounted Coagulation Profiles Clinical Laboratories.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.
Thrombophilia.
In the name of GOD.
CoPrincipal Investigators
Fertility and Sterility  Volume 98, Issue 5, Pages (November 2012)
Inherited thrombophilia Screening
Thrombophilia in pregnancy: Whom to screen, when to treat
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Presentation transcript:

ALIFE2 Study Call for participation Paulien de Jong Dr. Mariëtte Goddijn Prof. dr. Saskia Middeldorp

Disclosures Paulien de Jong Research contracts: - Consulting: Employment in industry: Stockholder of a healthcare company: Owner of a healthcare company: Other:

Rationale for the study Inherited thrombophilia is associated with pregnancy loss1,2 recurrent early loss: OR 1.9 – 2.72 Thrombosis of (micro-)vasculature of placenta Inhibition of throphoblast differentiation and subsequent placentation3 Possible therapy for pregnancy loss: anticoagulants ? 1. Rey, Lancet, 2003 2. Robertson, Br. J. of Haematology 2006 3. Quenby, Fertility and Sterility, 2005

ALIFE study 364 women Randomized 123 aspirin and nadroparin 121 placebo Live birth: 69% Live birth: 62% Live birth: 67% RR 1.03 RR 0.92 Reference RR 1.31 RR 1.22 Reference Inherited thrombophilia Kaandorp NEJM 2010

ALIFE2 study Objective: to evaluate the efficacy of LMWH in women with recurrent miscarriage and inherited thrombophilia Primary outcome: live birth Secondary outcomes: adverse pregnancy outcomes & safety Design: Multicenter, investigator-initiated study Open label

In-/exclusion criteria Inclusion criteria: ≥2 miscarriages and / or IUFDs Age 18-42 Confirmed inherited thrombophilia: Factor V Leiden mutation, prothrombin gene mutation, protein C deficiency, protein S deficiency, antithrombin deficiency Exclusion criteria: Pregnancy duration ≥ 7 weeks Indication for anticoagulant treatment during pregnancy (for instance prosthetic heart valves, a history of venous thromboembolism or antiphospholipid syndrome) Contraindications to LMWH (previous heparin induced thrombocytopenia, active bleeds or renal insufficiency with creatinine clearance of less than 30ml/min) Known allergy to at least 3 different LMWH preparations Previous inclusion in the ALIFE2 study (for another pregnancy)

In-/exclusion criteria Inclusion criteria: ≥2 miscarriages and / or IUFDs Age 18-42 Confirmed inherited thrombophilia: Factor V Leiden mutation, prothrombin gene mutation, protein C deficiency, protein S deficiency, antithrombin deficiency Exclusion criteria: Pregancy duration ≥7 weeks Indication for anticoagulant treatment during pregnancy (for instance prosthetic heart valves, a history of venous thromboembolism or antiphospholipid syndrome) Contraindications to LMWH (previous heparin induced thrombocytopenia, active bleeds or renal insufficiency with creatinine clearance of less than 30ml/min) Known allergy to at least 3 different LMWH preparations Previous inclusion in the ALIFE2 study (for another pregnancy)

® Primary efficacy outcome: Live birth M M Confirmed Inherited thrombophilia LMWH + standard pregnancy surveillance ® Recruitment delivery Follow-up M M Positive urine pregnancy test ≥ 2 miscarriages and/or IUFDs Standard pregnancy surveillance 6 weeks

Participating centers - AMC - Amphia - UMCG - Jeroen Bosch Ziekenhuis - VUMC - Isala Klinieken - MUMC - OLVG - UMCN - Maxima MC - UMCU Foreign centers: Brussels USA/UK/Canada/Australia…..

Inclusions n=399 Sample size Inclusions n=15

We are looking for you! Think of ALIFE2 in case of Recurrent miscarriage and/or IUFD Women with inherited thrombophilia Refer study candidates Contact us for questions regarding eligibility

www.ALIFE2study.org p.g.dejong@amc.uva.nl s.middeldorp@amc.uva.nl